CEFACLOR ANHYDROUS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C15H14ClN3O4S
Molecular Weight	367.807
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)C3=CC=CC=C3

InChI

InChIKey=QYIYFLOTGYLRGG-GPCCPHFNSA-N

InChI=1S/C15H14ClN3O4S/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23)/t9-,10-,14-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C15H14ClN3O4S
Molecular Weight	367.807
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.drugs.com/pro/cefaclor.html
Curator's Comment: description was created based on several sources, including: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/666290

Cefaclor is a semisynthetic cephalosporin antibiotic for oral administration. As with other cephalosporins, the bactericidal action of Cefaclor results from inhibition of cell-wall synthesis. Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae, staphylococci, and Streptococcus pyogenes; Lower respiratory tract infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae, and Streptococcus pyogenes; Pharyngitis and Tonsillitis, caused by Streptococcus pyogenes; Urinary tract infections, including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci; Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes. Adverse effects considered to be related to therapy with cefaclor are: Hypersensitivity reactions, Rarely, reversible hyperactivity, agitation, nervousness, insomnia, confusion, hypertonia, dizziness, hallucinations, somnolence and diarrhea. Patients receiving Cefaclor may show a false-positive reaction for glucose in the urine with tests that use Benedict's and Fehling's solutions and also with Clinitest® tablets. There have been reports of increased anticoagulant effect when Cefaclor and oral anticoagulants were administered concomitantly.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Canalicular multispecific organic anion transporter 1 21 Target ID: CHEMBL5748 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16434549	Inhibitor 8504	1.15 mM [Ki]
Oligopeptide transporter small intestine isoform 6 Target ID: CHEMBL4605 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16434549	Inhibitor 8504	4.52 mM [Ki]
Solute carrier family 15 member 2 8 Target ID: CHEMBL1743125 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16434549	Inhibitor 8504	65.0 µM [Ki]
Bacterial penicillin-binding protein 234 Target ID: CHEMBL2354204 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1622180 \| https://www.ncbi.nlm.nih.gov/pubmed/6373702 \| https://www.ncbi.nlm.nih.gov/pubmed/21502633 \| https://www.ncbi.nlm.nih.gov/pubmed/20713676	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Otitis media 42 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Curative	Approved 8583	CEFACLOR Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date 2002
Lower respiratory tract infections 52 Sources: https://www.drugs.com/pro/cefaclor.html	Curative	Approved 8583	CEFACLOR Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date 2002
Pharyngitis 31 Sources: https://www.drugs.com/pro/cefaclor.html	Curative	Approved 8583	CEFACLOR Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date 2002
Tonsillitis 36 Sources: https://www.drugs.com/pro/cefaclor.html	Curative	Approved 8583	CEFACLOR Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date 2002
Urinary tract infections 207 Sources: https://www.drugs.com/pro/cefaclor.html	Curative	Approved 8583	CEFACLOR Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date 2002
Skin and skin structure infections 81 Sources: https://www.drugs.com/pro/cefaclor.html	Curative	Approved 8583	CEFACLOR Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date 2002

C_max

Value	Dose	Co-administered	Analyte	Population
17.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2393282/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:		CEFACLOR plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
17.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2393282/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:		CEFACLOR plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
0.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2393282/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:		CEFACLOR plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Other AEs: Hypersensitivity... Other AEs: Hypersensitivity (1.5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Other AEs: Diarrhea... Other AEs: Diarrhea (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Other AEs: Eosinophilia, Pruritus genital... Other AEs: Eosinophilia (1 patient) Pruritus genital (1 patient) Moniliasis (1 patient) Vaginitis (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Other AEs: Aspartate aminotransferase increased, ALT increased... Other AEs: Aspartate aminotransferase increased (1 patient) ALT increased (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Other AEs: Alkaline phosphatase increased, Blood urea increased... Other AEs: Alkaline phosphatase increased (1 patient) Blood urea increased (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Other AEs: Creatinine serum increased... Other AEs: Creatinine serum increased (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
20 mg/kg/day 3 times / day steady, oral Dose: 20 mg/kg/day, 3 times / day Route: oral Route: steady Dose: 20 mg/kg/day, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, pediatric Health Status: unhealthy Age Group: pediatric Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Other AEs: Reaction serum sickness-like... Other AEs: Reaction serum sickness-like (0.5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf

AEs

AE	Significance	Dose	Population
Hypersensitivity	1.5%	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Diarrhea	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Eosinophilia	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Moniliasis	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Pruritus genital	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Vaginitis	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
ALT increased	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Aspartate aminotransferase increased	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Alkaline phosphatase increased	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Blood urea increased	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Creatinine serum increased	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Reaction serum sickness-like	0.5%	20 mg/kg/day 3 times / day steady, oral Dose: 20 mg/kg/day, 3 times / day Route: oral Route: steady Dose: 20 mg/kg/day, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, pediatric Health Status: unhealthy Age Group: pediatric Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
PEPT2 13 OAT1 725	PEPT2 37 OAT3 391 OAT1 395 PEPT1 60

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
OAT1 730	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/16434549/	yes [Ki 1150 uM]
PEPT2 17	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/16434549/	yes [Ki 65 uM]

Drug as victim

Target	Modality	Activity
OAT1 395	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16434549/	no
PEPT2 37	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16434549/	yes [Km 70.2 uM]
OAT3 391	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16098483/	yes
PEPT1 60	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16434549/	yes

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B1-01441	http://www.3bsc.com/index/pro_info.php?id=21653
3B Scientific (Wuhan) Corp	3B2-0069	http://www.3bsc.com/index/pro_info.php?id=19425
AA Blocks	AA00I9K4	https://www.aablocks.com/goods/Goods/detail?id=AA00I9K4
Aaron Chemicals	AR00IABW	http://www.aaronchem.com/53994-73-3
abcr GmbH	AB348868	http://www.abcr.com/shop/en/AB348868
AbMole Bioscience	M5483	http://www.abmole.com/products/cefaclor.html
Achemtek	0104-018667	http://www.achemtek.com/53994-73-3
Acros Organics	AC455260010	https://www.fishersci.com/shop/products/cefaclor-96-acros-organics-1/AC455260010
Acros Organics	AC455260050	https://www.fishersci.com/shop/products/cefaclor-96-acros-organics/AC455260050
Active Biopharma	ABP000537	http://www.activebiopharma.com/53994-73-3
AEchem Scientific Corp., USA	AE065370	https://www.aechemsc.com/info_products/AE065370.php
AHH Chemical co.,ltd	API-1060	http://www.ahhchemical.com/product/API-1060.html
Ambeed	A580945	https://www.ambeed.com/products/53994-73-3.html
ApexBio Technology	A5559	http://www.apexbt.com/cefaclor.html
Aurora Fine Chemicals LLC	A17.879.960	http://online.aurorafinechemicals.com/info?ID=A17.879.960
BenchChem	B193732	https://www.benchchem.com/product/b193732
BioCrick	BCC2527	http://www.biocrick.com/Cefaclor-BCC2527.html
BioSynth	C-2461	https://www.biosynth.com/products/biochemistry/culture-media-additives/products/C-2461.html
BLD Pharm	BD00860299	http://www.bldpharm.com/products/143059-69-2.html
BLD Pharm	BD120238	http://www.bldpharm.com/products/53994-73-3.html
Chem Scene	CS-2134	http://www.chemscene.com/53994-73-3.html
Chemspace	CSSB00016993337	https://chem-space.com/CSSB00016993337
Clearsynth	CS-O-06266	https://www.clearsynth.com/en/CSO06266.html
CSNpharm	CSN10559	https://www.csnpharm.com/products/cefaclor.html
eNovation Chemicals	D964471	https://www.enovationchem.com/ProductDetails.asp?ProductID=D964471
Glentham Life Sciences	GA0871	http://www.glentham.com/products/product/GA0871/
Huateng Pharma	F100322	http://en.huatengsci.com/product/Cefaclor.html
iChemical	EBD2197964	http://www.ichemical.com/products/53994-73-3.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network	LN01343473	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01343473
MedChem Express	HY-B0198	https://www.medchemexpress.com/Cefaclor.html
MuseChem	I003978	https://www.musechem.com/product/I003978.html
Parchem	28476	http://www.parchem.com/chemical-supplier-distributor/Cefaclor-018476.aspx
Sigma-Aldrich	72579_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/72579?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	C6895_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/c6895?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S061062	http://www.sinfoobiotech.com/product/1064465
Smolecule	S523055	http://www.smolecule.com/products/s523055
THE BioTek	bt-263286	https://www.thebiotek.com/product/inhibitors/bt-263286
THE BioTek	bt-308691	https://www.thebiotek.com/product/others/bt-308691

PubMed

Title	Date	PubMed
Oral pharmacokinetics of cefaclor in Mexican subjects.	2001	11797648
Desirable and undesirable immunotropic effects of antibiotics: immunomodulating properties of cefaclor.	2001 Dec	11806622
Etiologies of the urinary tract infections in a Yemeni City.	2001 Jul	11479641
Clinical and pro-host effects of cefaclor in prophylaxis of recurrent otitis media in HIV-infected children.	2001 Jul-Aug	11675909
Competition of IL-1 and IL-1ra determines lymphocyte response to delayed stimulation with PHA.	2001 Jun	11545246
Death from multi-resistant shigellosis in Fiji Islands.	2001 Mar	12017845
[Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1999). I. Susceptibility distribution].	2001 May	11510118
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.	2001 Nov	11792017
Antimicrobial susceptibility of nasopharyngeal isolates of Haemophilus influenzae from healthy children in day-care centres: results of multicentre study in Russia.	2001 Oct	11691567
Short-course therapy with cefaclor for treatment of streptococcal pharyngotonsillitis.	2001 Oct	11691566
High rates of multiple antibiotic resistance in Streptococcus pneumoniae from healthy children living in isolated rural communities: association with cephalosporin use and intrafamilial transmission.	2001 Oct	11581436
Release profile of antimicrobial agents from alpha-tricalcium phosphate cement.	2001 Oct	11545305
[Susceptibility to penicillin and 13 antimicrobial agents in erythromycin-resistant viridans group streptococci isolated from blood cultures].	2001 Sep	11753449
Penetration of cefaclor into the interstitial space fluid of skeletal muscle and lung tissue in rats.	2001 Sep	11683245
Cefditoren in vitro activity and spectrum: a review of international studies using reference methods.	2001 Sep-Oct	11687308
A comparative study of cefaclor vs. amoxicillin/clavulanate in tonsillopharyngitis.	2001 Sep-Oct	11535952
Levofloxacin: an updated review of its use in the treatment of bacterial infections.	2002	12269858
Immunoglobulin E binding determinants on beta-lactam drugs.	2002 Aug	12130943
Determination of antimicrobial activity of Cefaclor on common respiratory tract pathogens in Pakistan.	2002 Jan	11963587
Cutaneous and systemic manifestations of drug-induced vasculitis.	2002 Jan	11816242
Comparative study of cefaclor AF vs. cefuroxime axetil in acute exacerbations of chronic bronchitis.	2002 Jan	11782685
Foreign drug firm pleads guilty to felony charges.	2002 Jan-Feb	11881596
Comparative efficacy and safety of 5-day cefaclor and 10-day amoxycillin treatment of group A streptococcal pharyngitis in children.	2002 Jul	12127708
Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion.	2002 Jul	12114361
[Microbiological and clinical studies of Haemophilus influenzae isolated at Kitakyushu Municipal Medical Center from 1996 through 1999].	2002 Jun	12199114
The fecal microflora of 1-3-month-old infants during treatment with eight oral antibiotics.	2002 Jun	12120942
Susceptibility change to antibiotics of Staphylococcus aureus strains isolated from skin infections between July 1994 and November 2000.	2002 Jun	12111576
Trends in antimicrobial susceptibility of the Streptococcus milleri group.	2002 Jun	12111565
Serum sickness-like reactions.	2002 May	12041822
An evaluation of cefaclor in Pakistani children with pharyngotonsillitis.	2002 Oct	12553673
Cefaclor induced serum sickness like reaction.	2002 Oct	12450309
Mycobacterium bohemicum cervical lymphadenitis.	2002 Oct	12400532
The Italian Epidemiological Survey 1997-1999. Antimicrobial susceptibility data of Haemophilus influenzae, Haemophilus parainfluenzae and Moraxella catarrhalis in Italy.	2002 Oct	12385682
Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT antimicrobial surveillance programme during 1999-2000.	2002 Sep	12239225
Antimicrobial action of Nitens mouthwash (cetyltrimethylammonium naproxenate) on multiple isolates of pharyngeal microbes: a controlled study against chlorhexidine, benzydamine, hexetidine, amoxicillin, amoxicillin-clavulanate, clarithromycin, and cefaclor.	2002 Sep	12218263
Synthesis and biological activity of tris- and tetrakiscatecholate siderophores based on poly-aza alkanoic acids or alkylbenzoic acids and their conjugates with beta-lactam antibiotics.	2003	12705174
Drainage of liver abscess via laparoscopic trocar with local anesthesia.	2003 Apr	12709620
Natural antimicrobial susceptibilities of strains of 'unusual' Serratia species: S. ficaria, S. fonticola, S. odorifera, S. plymuthica and S. rubidaea.	2003 Apr	12654765
Serotype distribution and antimicrobial resistance patterns in Streptococcus pneumoniae isolates from hospitalized pediatric patients with respiratory infections in Shanghai, China.	2003 Aug	12913778
Natural antibiotic susceptibility of Proteus spp., with special reference to P. mirabilis and P. penneri strains.	2003 Feb	12678409
[In vitro sensitivity to antimicrobial agents of Haemophilus influenzae strains isolated from clinical specimens].	2003 Jan	12838674
[Antibiotic resistance and serotype distribution of Streptococcus pneumoniae strains isolated from patients at Hacettepe University Medical Faculty].	2003 Jan	12838672
Effect of extended-spectrum beta-lactamases on the susceptibility of Haemophilus influenzae to cephalosporins.	2003 Jan	12493785
Determination of cefaclor in human plasma by a sensitive and specific liquid chromatographic-tandem mass spectrometric method.	2003 Jan 25	12504178
Natural antibiotic susceptibility of strains of Serratia marcescens and the S. liquefaciens complex: S. liquefaciens sensu stricto, S. proteamaculans and S. grimesii.	2003 Jul	12842326
A comparative study of cefaclor vs amoxicillin/clavulanate in pediatric pharyngotonsillitis.	2003 Mar	12640354
Surveillance of antibiotic resistance in clinical isolates of Streptococcus pneumoniae collected in Belgium during winter 2000-2001.	2003 Mar-Apr	12836494
[Report of questionnaire survey for methicillin-resistant Staphylococcus aureus and penisillin-resistant Streptococcus pneumoniae between 1998 and 2000 in the Kinki district].	2003 May	12806929
Antibiotic prophylaxis by low-dose cefaclor in children with vesicoureteral reflux.	2003 May	12736811
[Hypersensitivity reactions to beta-lactam antibiotics in childhood].	2003 May-Jun	12783760

Patents

Sample Use Guides

In Vivo Use Guide

The usual adult dosage is 250 mg every 8 hours. For more severe infections (such as pneumonia) or those caused by less susceptible organisms, doses may be doubled.

Route of Administration: Oral

In Vitro Use Guide

Cefaclor inhibits the gram-negative bacteria. At a level of 12.5 ug/ml, 73% of the E. coli, 90% of the Salmonella, 55% of the Shigella, 77% of the Citrobacter, 91% of the Klebsiella, and 75% of the P. mirabilis isolates were inhibited. However, only 18% of the Enterobacter, 3% of the Serratia, 9% of the Proteus morganii, and 16% of the Providencia strains, and less than 10% of the Proteus vulgaris, Proteus rettgeri, and Bacteroides fragilis isolates, were inhibited. All Pseudomonas strains were as resistant to cefaclor as they were to available cephalosporins.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:07:10 GMT 2025` Edited by `admin` on `Mon Mar 31 18:07:10 GMT 2025`
Record UNII	3Z6FS3IK0K
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CEFACLOR ANHYDROUS

Common Name

English

CEFACLOR [MI]

Preferred Name

English

Cefaclor [WHO-DD]

Common Name

English

CEFACLOR IMPURITY C [EP IMPURITY]

Common Name

English

cefaclor [INN]

Common Name

English

CEFACLOR [JAN]

Common Name

English

5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-(((2R)-2-AMINO-2-PHENYLACETYL)AMINO)-3-CHLORO-8-OXO-, (6R,7R)-

Common Name

English

(6R,7R)-7-(((2R)-2-AMINO-2-PHENYLACETYL)AMINO)-3-CHLORO-8-OXO-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID

Systematic Name

English

Classification Tree Code System Code

NDF-RT

N0000175488